Systematic review, meta-analysis and economic modelling of ...

More documents

Recommendations

Info

Assessment of diagnostic and prognostic accuracyTABLE 6 Index and reference standard tests used in studies of TnTStudy Index test assayIndex testthreshold (µg/l)99thpercentile,10% CV andLoD (µg/l) Reference troponin assay and timing a Reference troponinthreshold (µg/l) Prevalence MI (%)Body 2011 46 Roche Diagnostics Elecsys fourthgenerationTnT0.01 0.010.035Not statedRoche fourth-generation TnT at 12 hours 0.035 18Cete 2010 58 Not stated 0.1 Not stated Unspecified TnT at 6 hours 0.1 33Christ 2010 60 Roche Diagnostics Elecsys fourthgenerationTnT0.010.040.010.035Not statedRoche fourth-generation TnT at 6 hoursafter presentation0.04 15Christ 2010 60 Roche Diagnostics Elecsys HsTnT 0.0030.0140.0140.0130.002Roche fourth-generation TnT at 6 hoursafter presentation0.04 15Collinson Roche Diagnostics Elecsys thirdgeneration2006 62 TnT0.03 0.010.030.01Roche third-generation TnT at 24 hours 0.05 29Haltern 2010 67 Roche Diagnostics Elecsys TnT 0.03 0.01Roche TnT at 12 hours 0.03 330.030.01Keller 2009 20 Roche Diagnostics Elecsys TnT 0.010.030.010.030.01Roche TnT or Siemens Dimension RxL TnIwithin 6 hours of admission0.3 (TnT)0.14 (TnI)2926NIHR Journals Library
DOI: 10.3310/hta17010 Health Technology Assessment 2013 Vol. 17 No. 1Study Index test assayIndex testthreshold (µg/l)99thpercentile,10% CV andLoD (µg/l) Reference troponin assay and timing a Reference troponinthreshold (µg/l) Prevalence MI (%)Li 2010 73 Not stated 0.1 Not stated Unspecified TnT at 12 hours 0.1 50McCann Roche Diagnostics Elecsys TnT 0.03 0.012008 76 0.030.01Roche TnT at 12 hours 0.03 48Naroo 2009 78 Electrochemiluminescenceimmunoassay0.03 Not stated Electrochemiluminescence immunoassayTnT at 6–12 hours after presentation1 13Reichlin 2009 19 Roche Diagnostics Elecsys HsTnT 0.0140.0020.0140.0130.002Abbott AxSYM TnI, Beckman CoulterAccuTnI or Roche TnT at 6–9 hours afterpresentation99th percentile 17Reichlin 2009 19 Roche Diagnostics, Elecsysfourth-generation TnT0.0350.010.010.0350.01Abbott AxSYM TnI, Beckman CoulterAccuTnI or Roche TnT at 6–9 hours afterpresentation99th percentile 17Valle 2008 82 Not stated Not stated Not stated Unspecified TnT at 6–12 hours Not stated 35a Timing is from symptoms unless otherwise specified.© Queen’s Printer and Controller of HMSO 2013. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of Statefor Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journalsprovided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should beaddressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton SciencePark, Southampton SO16 7NS, UK.27
Page 1: Health Technology AssessmentVOLUME
Page 7: DOI: 10.3310/hta17010 Health Techno
Page 10 and 11: ContentsAppendix 5 Expected discoun
Page 13 and 14: DOI: 10.3310/hta17010 Health Techno
Page 19: DOI: 10.3310/hta17010 Health Techno
Page 22 and 23: BackgroundTABLE 1 Hospital admissio
Page 24 and 25: Background2. investigation of the c
Page 26 and 27: BackgroundComputed tomographic coro
Page 28 and 29: Research questionsiii. the diagnost
Page 30 and 31: Assessment of diagnostic and progno
Page 97 and 98:
DOI: 10.3310/hta17010 Health Techno
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125:
Page 128 and 129:
Discussionspecificity were 62% (95%
Page 130 and 131:
Discussionneed for revascularisatio
Page 132 and 133:
Discussionchanges in sensitivity an
Page 134 and 135:
Discussionuncertainty about these p
Page 136 and 137:
Discussiontroponin assays have bett
Page 138 and 139:
ConclusionsSuggested research prior
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151:
Page 154 and 155:
Appendix 144. heart-type fatty acid
Page 156 and 157:
Appendix 1135. interleukin 33.mp. (
Page 158 and 159:
Appendix 147. 37 and 45 (529)48. li
Page 161:
Page 164 and 165:
Appendix 313. Fernandez Portales JG
Page 166 and 167:
Appendix 346. Luscher MS, Ravkilde
Page 168 and 169:
Appendix 316. Rao SV, Ohman EM, Gra
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195:
Page 198 and 199:
Appendix 9Clinical diagnosis of NST
Page 200 and 201:
Appendix 9respectively. Exercise EC
Page 202 and 203:
Appendix 93. Two reviewers will mak
Page 204 and 205:
Appendix 9The methodology used in t
Page 206 and 207:
Appendix 9ES (Information Resources
Page 208:
Appendix 923. Westwood ME, Whiting
show all

Systematic review, meta-analysis and economic modelling of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?